Mirzaten Q-Tab (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten Q-Tab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirzaten Q-Tab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used in the treatment of depressive disorders, acting on noradrenergic and serotonergic pathways.

Major depressive disorder: improves mood, sleep and appetite in adult patients. Treatment‑resistant depression: may be added as adjunct therapy when first‑line agents are insufficient. Depression with anxiety: helps reduce both depressive and anxiety symptoms.

Mirtazapine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Sedation or drowsiness: especially at treatment initiation. - Increased appetite and weight gain: often observed with continued use. - Dry mouth: may lead to mild discomfort. - Constipation: can be managed with dietary measures.

Serious or Rare Side Effects: - Agranulocytosis or neutropenia: requires regular blood monitoring. - Seizures: reported rarely, particularly in predisposed individuals. - Severe allergic reactions: including rash, angioedema or anaphylaxis.

Before prescribing Mirzaten Q-Tab, clinicians should consider several safety aspects. - Weight monitoring: due to potential weight gain. - Sedation assessment: advise patients about operating machinery. - Hepatic impairment: dose adjustment may be needed. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Elderly patients: start at lower doses and monitor for confusion. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Other serotonergic agents: potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - Antihypertensive drugs: possible additive blood pressure lowering. - Anticholinergic medications: may exacerbate dry mouth and constipation. - Oral contraceptives: may alter hormonal efficacy.